Literature DB >> 1718493

Alpha 2-macroglobulin binds and inhibits activated protein C.

H Hoogendoorn1, C H Toh, M E Nesheim, A R Giles.   

Abstract

In previous studies using a nonhuman primate model of Protein C (PC) activation in vivo, immunoblotting showed substantial amounts of activated PC (APC) in a high molecular weight complex with what was presumed to be a previously unrecognized APC binding protein. This APC complex can also be formed in citrated plasma in vitro. It is of low electrophoretic mobility, sodium dodecyl sulfate (SDS) stable, with an apparent Mr of 320 Kd. Its purification from human plasma was accomplished using barium citrate adsorption, sequential polyethylene glycol (PEG) precipitations, diethylaminoethyl sepharose chromatography, AcA-34 gel filtration, and zinc-chelate affinity chromatography. This was monitored by subjecting the fractions to nondenaturing polyacrylamide gel electrophoresis (PAGE), transfer to polyvinylidene-difluoride membranes, and probing with 125I-labeled human APC. The purified APC-binding protein was homogeneous by SDS-PAGE with an Mr of 275 Kd. Its identity as alpha 2-macroglobulin (alpha 2M) was demonstrated immunochemically. Complex formation between alpha 2M and APC was found to be almost completely inhibited by EDTA, but to a lesser extent by citrate. Complex formation could also be prevented by active site inhibition with D-Phenylalanyl-L-Prolyl-L-Arginine-Chloromethyl Ketone (PPACK) or pretreatment of alpha 2M with methylamine. Incubation of APC (33 nmol/L) with alpha 2M (1 mumol/L) resulted in time-dependent inhibition of APC anticoagulant activity when measured using an activated partial thromboplastin time based APC assay. These data show that alpha 2M binds and inhibits APC in vitro and the interaction is both metal-ion and active-site dependent, requiring functionally intact alpha 2M. As the complexes formed in vitro comigrate electrophoretically with those observed in vivo after PC activation, it is suggested that alpha 2M is a physiologically relevant inhibitor involved in the processing of APC in vivo.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1718493

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Inflammatory and metalloproteinases profiles predict three-month poor outcomes in ischemic stroke treated with thrombolysis.

Authors:  Anna Maria Gori; Betti Giusti; Benedetta Piccardi; Patrizia Nencini; Vanessa Palumbo; Mascia Nesi; Antonia Nucera; Giovanni Pracucci; Paolina Tonelli; Eleonora Innocenti; Alice Sereni; Elena Sticchi; Danilo Toni; Paolo Bovi; Mario Guidotti; Maria Rosaria Tola; Domenico Consoli; Giuseppe Micieli; Rossana Tassi; Giovanni Orlandi; Maria Sessa; Francesco Perini; Maria Luisa Delodovici; Maria Luisa Zedde; Francesca Massaro; Rosanna Abbate; Domenico Inzitari
Journal:  J Cereb Blood Flow Metab       Date:  2017-03-07       Impact factor: 6.200

2.  Prospective plasma proteome changes in preterm infants with different gestational ages.

Authors:  Maciej Suski; Renata Bokiniec; Monika Szwarc-Duma; Józef Madej; Beata Bujak-Giżycka; Przemko Kwinta; Maria Katarzyna Borszewska-Kornacka; Cecilie Revhaug; Lars O Baumbusch; Ola D Saugstad; Jacek Józef Pietrzyk
Journal:  Pediatr Res       Date:  2018-05-23       Impact factor: 3.756

3.  Single cell transcriptomics identifies focal segmental glomerulosclerosis remission endothelial biomarker.

Authors:  Rajasree Menon; Edgar A Otto; Paul Hoover; Sean Eddy; Laura Mariani; Bradley Godfrey; Celine C Berthier; Felix Eichinger; Lalita Subramanian; Jennifer Harder; Wenjun Ju; Viji Nair; Maria Larkina; Abhijit S Naik; Jinghui Luo; Sanjay Jain; Rachel Sealfon; Olga Troyanskaya; Nir Hacohen; Jeffrey B Hodgin; Matthias Kretzler; Kidney Precision Medicine Project Kpmp
Journal:  JCI Insight       Date:  2020-03-26

4.  α2-Macroglobulin Is a Significant In Vivo Inhibitor of Activated Protein C and Low APC:α2M Levels Are Associated with Venous Thromboembolism.

Authors:  Laura Martos; Luis Andrés Ramón; Julia Oto; Álvaro Fernández-Pardo; Santiago Bonanad; Ana Rosa Cid; Andras Gruber; John H Griffin; Francisco España; Silvia Navarro; Pilar Medina
Journal:  Thromb Haemost       Date:  2018-02-15       Impact factor: 5.249

5.  Alpha-2-macroglobulin functions as an inhibitor of fibrinolytic, clotting, and neutrophilic proteinases in sepsis: studies using a baboon model.

Authors:  J P de Boer; A A Creasey; A Chang; J J Abbink; D Roem; A J Eerenberg; C E Hack; F B Taylor
Journal:  Infect Immun       Date:  1993-12       Impact factor: 3.441

6.  Alpha2-macroglobulin as a promising biomarker for cerebral small vessel disease in acute ischemic stroke patients.

Authors:  Tomohisa Nezu; Naohisa Hosomi; Shiro Aoki; Kazushi Deguchi; Hisashi Masugata; Noriko Ichihara; Hideo Ohyama; Toshiho Ohtsuki; Masakazu Kohno; Masayasu Matsumoto
Journal:  J Neurol       Date:  2013-07-23       Impact factor: 4.849

7.  Alpha-2-macroglobulin as a Promising Biological Marker of Endothelial Function.

Authors:  Ryo Shimomura; Tomohisa Nezu; Naohisa Hosomi; Shiro Aoki; Takamichi Sugimoto; Naoto Kinoshita; Mutsuko Araki; Tetsuya Takahashi; Hirofumi Maruyama; Masayasu Matsumoto
Journal:  J Atheroscler Thromb       Date:  2017-11-01       Impact factor: 4.928

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.